EANS-Adhoc: LifeWatch receives CE mark for its LifeWatch V health smart phone (with document)
Ein Dokument
--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------
Justice/Processes/New Products/LifeWatch AG
06.12.2012
Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless remote cardiac and medical patient monitoring service
provider in the U.S., today reports that its LifeWatch V health smartphone
platform was awarded the CE Mark (Number 2074225CE02). The CE Mark allows
LifeWatch AG to launch its new LifeWatch V in Europe.
You will find a PDF-version of this press release at the end of this message.
A CE mark confirms that the LifeWatch V system has met the applicable directives
of the European Commission (EC) and as such, can be marketed to the 30-nation
EEA and Switzerland. The LifeWatch V is a fully featured state-of-the-art
smartphone that allows patients and health- and wellbeing-conscious consumers to
self-operate a wide range of embedded medical sensors, wellness-related
applications, cloud-based services and 24/7 call center support.
By using the barely visible sensors on the phone's frame, patients and health-
and wellness consumers can track, capture, collect and analyze their health
measurements anywhere anytime. The sensors include ECG, body temperature, blood
glucose, heart rate, blood oxygen saturation, body fat percentage and stress
analysis measurement. All of the collected data can be retrieved from the cloud
for a follow-up. Users can take corrective action, plan diets and activities,
securely share the information with a health provider or family member, trend
and analyze the data and more. Patients may also program the LifeWatch V to
remind them of their drug type, dose and intake time.
The LifeWatch V handset unit includes a service enablement platform to support
the transmission of medical data to be analyzed, evaluated and communicated to
health professionals and call center personnel around the clock. The device
wirelessly interacts with a cloud-based environment allowing its' users direct
access to a wide range of complementary medical and wellness related services.
The LifeWatch V smartphone is an important milestone on the Company's way
towards more diversification into new service areas such as the consumer and
wellness markets and into new geographies.
"This is the first time in the company's history that a multi-parameter device
with five medical functions has been awarded the CE Mark", stated Dr. Yacov
Geva, Chairman of LifeWatch AG. "The approval demonstrates our capacity to
develop and manufacture devices that meet commercial regulatory requirements not
only in the U.S. but also in Europe and elsewhere".
LifeWatch is currently in discussions with a number of multi-national cell
carriers, pharmaceutical and healthcare providers all over the world on
partnership opportunities of the LifeWatch V.
About LifeWatch AG:
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch AG has operative subsidiaries in the United States, in
Switzerland and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading US-based
provider of cardiac monitoring services and home sleep testing of Obstructive
Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading
developer and manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical sensors and
apps that uses a cloud-based service platform. For additional information,
please visit {www.lifewatch.com}[HYPERLINK: http://www.lifewatch.com].
Sign-up for customized email alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/
This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE
AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES
OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED
WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN
APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH
AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION
ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE
ISSUER.
Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/fwg66J4J
Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch
end of announcement euro adhoc
--------------------------------------------------------------------------------
Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/fwg66J4J
issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English